Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study

Adam S. Kibel(Brigham and Women's Hospital), Mario A. Eisenberger(Johns Hopkins University), Mitchell C. Benson(Columbia University), Eli Rosenbaum(Johns Hopkins University), Elizabeth Garrett‐Mayer(Novartis (Switzerland)), Joel Picus(Washington University in St. Louis), Bruce J. Roth, Christopher W. Ryan(Oregon Health & Science University), Tomasz M. Beer(Exact Sciences (United States)), Daniel P. Petrylak(Yale University), Michael S. Cookson(University of Oklahoma Health Sciences Center), Michael W. Kattan(Unknown), George Wilding(The University of Texas MD Anderson Cancer Center), Alan W. Partin(Johns Hopkins University), Gurkamal Chatta(Roswell Park Comprehensive Cancer Center), Robert Dreicer(University of Virginia), Robert S. DiPaola(University of Kentucky), Eric A. Klein(Meta (United States)), Joel B. Nelson(University of Pittsburgh), David F. Jarrard(University of Wisconsin System)
The Journal of Urology
April 15, 2007
10.1016/j.juro.2007.01.028
Cited by 47

Related Papers

Assessing the Performance of Prediction Models
|Epidemiology|2009|4.9k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k